DELTICOM
7.4.2016 15:07:25 CEST | Business Wire | Press release
Springtime is tyre-changing time. However, some people who have been driving on old winter tyres might consider wearing them out completely by leaving them for all summer, thus saving themselves the cost of having the tyres changed as well as the possible cost of a new set of summer tyres. By doing so, they sacrifice their own safety and purchasing efficiency.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160407005795/en/
The properties of summer and winter tyres are designed to meet the specific requirements of weather conditions at different times of year. In this way, they ensure optimum efficiency and safety in the prevailing weather conditions. While it may be very tempting to drive straight through to autumn on winter tyres, in warm temperatures summer tyres are a better choice. The general rule of thumb is: from Easter to October. Once the average temperature is mostly above seven degrees Celsius, summer tyres show off all their advantages.
Even Germany’s largest automobile association, ADAC, warns against driving on winter tyres during summer. The reason: due to the soft tread compound used in winter tyres, they are not suited to warm temperatures and offer less grip. When the weather gets warmer, the tread quickly wears off and braking performance is significantly affected. ADAC tests on winter tyres have shown that in summer, stopping distances at approx. 60mph/h may be extended by up to 16 metres. If tyres are also heated further through heavy vehicle loads, winter tyre side walls can suffer damage, and parts of the tread can even come unstuck.
“We recommend changing to summer tyres now, because they are the only tyres that offer the right custom profile and special rubber compound for warmer weather and therefore ensure good grip and shorter breaking distances”, advises Thierry Delesalle from Mytyres.co.uk. “If you’re thinking of leaving your winter tyres on, you won’t do your wallet any favours: in warm weather, winter tyres can increase fuel consumption by up to 15%”, explains Delesalle.
So save now and hit the road properly equipped: just click on Mytyres.co.uk and enjoy a wide range of suitable summer tyres at great prices - quickly, easily and securely. Tyres can be delivered either to the customer’s preferred address, or to one of over 2,000 partner fitting stations across the UK. Many partner workshops also offer customers competitive prices for storing their winter tyres at the workshop until the following winter.
The most important hints on the changing of summer tyres can be also found in the following video: https://www.youtube.com/watch?v=OE5wWgUmi2k&nohtml5
About Mytyres.co.uk
There are over 100 tyre brands and more than 25,000 models of tyres to be found at Mytyres.co.uk - also including the latest best-rated tyres from official comparison tests. The product portfolio not only includes tyres for cars , motorbikes , lorries, commercial vehicles and buses , but also wheel-tyre sets , rims and car replacement parts and accessories . Particularly practical: new tyres can be delivered quickly and free of charge* to any address provided. When purchasing tyres, buyers can also choose from more than 2,000 professional car workshop partners across the UK and have the tyres sent to them directly for professional fitting. Many of our partner workshops offer also additional services, such as tyre storage.
*2 tyres and more
Buy tyres online:
www.mytyres.co.uk , www.reifendirekt.de , www.reifendirekt.at , www.reifendirekt.ch , www.123pneus.ch , www.autobandenmarkt.nl , www.123pneus.fr , www.gommadiretto.it , www.neumaticos-online.es and in many other Delticom online shops.
Tyre tests: www.tyretest.com
Information about the company: www.delti.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160407005795/en/
Contact:
insignis Agency for Kommunikation GmbH (GPRA)
Henning Jahns
Tel.:
+49-511-132214-14
Fax: +49-511-132214-99
delticom@insignis.de
or
Delticom
AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax:
+49-511-93634-8301
anne.lena.peters@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom